Failed Resolution of Inflammation in Intracerebral Haemorrhage: New Therapeutic Targets Emerge
Key Insights
Intracerebral haemorrhage (search) (ICH) remains a devastating stroke subtype with limited treatment options, and chronic nonresolving neuroinflammation is now recognized as a key driver of secondary brain injury and poor outcomes.
The NLRP3 (search) inflammasome–ROS vicious cycle has been identified as a central mechanism perpetuating neuroinflammation after ICH, with targeting strategies showing promise in preclinical models.
Microglial HDAC3 (search) inhibition via BRD3308 modulates pyroptosis through the PPARγ (search)/NLRP3 (search)/GSDMD pathway, improving neurological function in experimental intraventricular hemorrhage.
Intracerebral haemorrhage (search) (ICH) accounts for a disproportionate share of stroke-related morbidity and mortality worldwide, yet therapeutic options remain severely limited. While acute surgical evacuation and blood pressure management have formed the cornerstone of care, a growing body of evidence now points to chronic, nonresolving neuroinflammation as a critical determinant of long-term outcomes. A comprehensive review published in Nature Reviews Neurology synthesizes current understanding of failed inflammatory resolution after ICH, highlighting emerging molecular targets that could reshape the treatment landscape.
The Burden of Unresolved Neuroinflammation
ICH triggers a complex cascade of inflammatory events beginning with the extravasation of blood components into the brain parenchyma. Blood-derived factors including hemoglobin, heme, iron, and plasma proteins initiate both direct neurotoxicity and robust immune activation. Microglia, the brain's resident immune cells, adopt a pro-inflammatory phenotype in the acute phase, releasing cytokines, matrix metalloproteinases (MMPs), and reactive oxygen species that contribute to blood–brain barrier disruption and perihematomal edema.
Under physiological conditions, this inflammatory response should transition toward resolution, characterized by efferocytosis—the clearance of apoptotic cells and debris—and tissue repair. In ICH, however, this transition frequently fails. As Nathan and Ding articulated in their foundational work on nonresolving inflammation, persistent inflammatory stimuli overwhelm endogenous resolution mechanisms, leading to chronic tissue damage. In the context of ICH, this manifests as sustained microglial activation, ongoing white matter injury, and progressive cognitive decline observed in survivors.
The NLRP3 (search)–ROS Axis: A Vicious Cycle
Central to the perpetuation of post-ICH neuroinflammation is the NLRP3 (search) inflammasome. Cao and colleagues, writing in the Journal of Inflammation Research, describe an oxidative-inflammatory vicious cycle in which reactive oxygen species (ROS) activate the NLRP3 inflammasome, which in turn drives further ROS production and pro-inflammatory cytokine release. This self-reinforcing loop represents a particularly attractive therapeutic node because interrupting it at multiple points could theoretically break the cycle.
Preclinical studies targeting the NLRP3 (search)–ROS axis have shown promise. Pharmacological inhibition of NLRP3 assembly, ROS scavenging, and downstream blockade of interleukin-1β signaling have all demonstrated neuroprotective effects in animal models of ICH. Notably, the BLOC-ICH phase II trial evaluated the interleukin-1 receptor antagonist anakinra in ICH patients, representing one of the first clinical attempts to modulate this pathway, though results remain preliminary.
HDAC3 (search): A Master Regulator of Microglial Pyroptosis
Histone deacetylase 3 (HDAC3 (search)) has emerged as a critical regulator of microglial inflammatory responses after ICH. Li and colleagues demonstrated that the HDAC3 inhibitor BRD3308 modulates microglial pyroptosis and neuroinflammation through the PPARγ (search)/NLRP3 (search)/GSDMD signaling axis, leading to improved neurological function in a mouse model of intraventricular hemorrhage. This work, published in Neuropharmacology, established HDAC3 as a druggable target for post-hemorrhagic neuroinflammation.
Subsequent studies have reinforced these findings. Watson and colleagues reported that conditional deletion of microglial HDAC3 (search) attenuates neurological deficits after ICH in mice. The therapeutic relevance extends beyond hemorrhagic stroke: Liao and colleagues showed that HDAC3 inhibition ameliorates ischemia/reperfusion-induced brain injury by regulating the microglial cGAS-STING pathway, suggesting broader applicability across stroke subtypes.
FPR1 (search) Signaling: A New Frontier
Formyl peptide receptor 1 (FPR1 (search)) has recently been identified as a potent driver of inflammatory brain injury. Li and colleagues, reporting in Science Translational Medicine, demonstrated that FPR1 signaling potentiates inflammatory brain injury following ICH. Building on this, the same group showed in Science that targeting FPR1 reduces brain inflammation and neurodegeneration, positioning this receptor as a high-value therapeutic target.
The translational potential of FPR1 (search) antagonism is supported by the existence of pharmacological tools such as HCH6-1, an FPR1 antagonist that has demonstrated anti-neuroinflammatory and neuroprotective effects in cellular and animal models of Parkinson's disease, suggesting that FPR1-directed therapies could have applications across multiple neurological conditions.
White Matter Injury and Remyelination Failure
Beyond gray matter damage, ICH induces significant white matter injury that contributes to long-term functional deficits. Neuroinflammation plays a central role in this process, with activated microglia and astrocytes disrupting oligodendrocyte survival and impairing remyelination. Xiao and colleagues, in Current Neuropharmacology, detailed how NLRP3 (search) inflammasome-mediated neuroinflammation drives secondary white matter injury after ICH.
Therapeutic strategies aimed at restoring myelin integrity are gaining traction. Wang and colleagues demonstrated that microglial lipocalin-2 (Lcn2) knockout enhances chronic ICH recovery by restoring myelin and reducing inflammation, as reported in Theranostics. Similarly, modified exosomal SIRPα variants have shown efficacy in alleviating white matter injury through modulation of microglia/macrophage function.
Efferocytosis: Restoring Resolution
Efferocytosis—the phagocytic clearance of dying cells and debris—is essential for the resolution of inflammation. Gao and colleagues, writing in the Chinese Medical Journal, identified efferocytosis as a new therapeutic target for stroke, noting that impaired clearance of apoptotic cells perpetuates inflammation and impedes tissue repair. Zhang and colleagues similarly highlighted the role of efferocytosis in the resolution of inflammation in cardiovascular and cerebrovascular disease.
Liver X receptor (LXR (search)) signaling has emerged as a key regulator of efferocytosis. Zhang and colleagues reported in Stroke and Vascular Neurology that enhanced LXR signaling reduces brain injury and promotes tissue regeneration following experimental ICH, with effects mediated through microglia/macrophages. Zang and colleagues further showed that LXR-β regulates microglial efferocytosis and neuroinflammation via STAT6 activation.
Therapeutic Implications and Future Directions
The recognition that failed resolution of inflammation drives poor outcomes after ICH has opened new therapeutic avenues. Strategies under investigation include NLRP3 (search) inflammasome inhibitors, HDAC3 (search) inhibitors, FPR1 (search) antagonists, and agents that enhance efferocytosis. Additionally, cell-based therapies using mesenchymal stem cells and their extracellular vesicles have shown promise in preclinical models by modulating neuroinflammation and promoting tissue repair.
The heterogeneity of ICH—varying by location, volume, and patient characteristics—presents challenges for clinical translation. However, the convergence of preclinical findings on key inflammatory pathways suggests that immunomodulatory strategies targeting the resolution of inflammation may finally address the unmet need for therapies that improve long-term recovery after intracerebral haemorrhage (search).